Trends in Cancer
ForumDiagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer
Section snippets
Concluding Remarks and Future Perspectives
Approaches based on cfDNA and ctDNA methylation analysis provide new avenues for early detection of various cancer types, and DNA methylation signatures hold a great potential to become routine clinical cancer biomarkers due to their sensitivity, specificity, and ease of analysis. Although the feasibility of cfDNA methylation analysis alone for cancer detection and monitoring has been successfully demonstrated, combining cfDNA mutation markers with classical biochemical cancer markers and/or
Acknowledgments
We are grateful to the many scientists who have contributed to this field but whose work was not cited due to space limitations.
References (16)
CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA
Genome Biol.
(2017)Liquid biopsies come of age: towards implementation of circulating tumour DNA
Nat. Rev. Cancer
(2017)Cancer epigenetics: an introduction
Methods Mol. Biol.
(2015)Detection and localization of surgically resectable cancers with a multi-analyte blood test
Science
(2018)Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Nature
(2018)The power and the promise of DNA methylation markers
Nat. Rev. Cancer
(2003)Cancer prevention: epigenetics steps up to the plate
Cancer Prev. Res.
(2008)DNA methylation markers for diagnosis and prognosis of common cancers
Proc. Natl. Acad. Sci. U. S. A.
(2017)
Cited by (55)
Liquid biopsy in the clinical management of cancer patients
2023, Molecular and Cellular ProbesPerformance of a targeted methylation-based multi-cancer early detection test by race and ethnicity
2023, Preventive MedicineCitation Excerpt :Zavala et al., 2021; Cancer Disparities - National Cancer Institute, 2022) Screening assays using patterns of DNA methylation as cancer biomarkers are one promising tool.(van der Pol and Mouliere, 2019 ; Roy and Tiirikainen, 2020) As some evidence suggests DNA methylation patterns may differ between racial and ethnic subpopulations,(Zhang et al., 2011; Pinzon Cortes and El-Osta, 2021) care must be taken to confirm consistent performance of novel screening technologies across the general population. A multi-cancer early detection (MCED) test (Galleri®) that analyzes methylation patterns in plasma cell-free DNA can detect a shared cancer signal across multiple cancer types and predict the cancer signal origin (CSO) from a single blood draw.
Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC
2023, Translational OncologyCitation Excerpt :Thus, it is necessary to develop simple, user-friendly, and reliable molecular markers to classify the prognosis of CRC patients [6]. Various biomarkers or classifiers, such as DNA, RNA (including circulating tumor DNA and RNA), protein, epigenetic (such as DNA methylation) and immunologic biomarkers, have recently been developed to predict the prognosis of patients with CRC, particularly their recurrence risk [7–13]. However, additional prospective clinical trials are needed to evaluate the predictive accuracy and efficiency of these putative biomarkers.
MicroRNAs and long non-coding RNAs in pancreatic cancer: From epigenetics to potential clinical applications
2023, Translational OncologyCitation Excerpt :Similarly, it has been noticed that the methylation of diverse microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), such as miR‑29b‑3p, LINC00901, ANRIL, and LIFR-AS1 contributes to PC progression [30–33]. Innovative protocols for the isolation and analysis of tumor-derived fraction of circulating cell-free DNA (cfDNA), such as liquid biopsies, have an optimistic potential for early diagnosis of cancers via detecting methylations, point mutations, gene fusions, among other cancer-related signatures [34–36]. In the pharmacological context, several types of therapeutic approaches for PC have been explored over the last decade, such as poly-ADP-ribose polymerase (PARP) inhibitors (e.g., olaparib, veliparib, rucaparib, and talazoparib), mitogen/extracellular signal-related kinase (MEK) inhibitors, EGFR inhibitors, KRAS targeting agents, JAK/STAT inhibitors, hydroxychloroquine, immunotherapy, and electrochemotherapy.
Novel 3D-Printed Microfluidic Magnetic Platform for Rapid DNA Isolation
2024, Analytical Chemistry